Table 4.
Response to DC therapy (SD stable disease, PD progressive disease, MR mixed response)
| Patient | DTHa | Tumor marker | Before | After | Clinical response | ||
|---|---|---|---|---|---|---|---|
| First | Second | Third | |||||
| 1 | − | AFP (ng/ml) | 3797 | 6446 | SD | ||
| 2 | ++ | None | SD | ||||
| 3 | − | PIVKA-II (ng/ml) | 14.8 | 113.3 | SD | ||
| 4 | − | AFP (ng/ml) | 5576 | 10154 | PD | ||
| 5 | + | PIVKA-II (ng/ml) | <10 | 125.8 | 400.2 | SD | |
| 6 | + | AFP (ng/ml) | 5.3 | 7.1 | PD | ||
| 7 | ++ | AFP (ng/ml) | 50.7 | 78.2 | 148 | 293.4 | MR |
| PIVKA-II (ng/ml) | 1350 | 894.4 | 1718 | >2000 | |||
| 8 | ++ | CA19-9 (U/ml) | 116.3 | 121.7 | 85.3 | SD | |
| 9 | ++ | AFP (ng/ml) | 128 | 94.5 | SD |
||
| PIVKA-II (ng/ml) | 325.4 | 76.2 | |||||
| 10 | ++ | None | PD | ||||
aDTH to KLH. Erythema and/or induration after 48 h: − <5 mm diameter, + 5–50 mm, ++ >50 mm